CENTER OF EXCELLENCE IN DIABETES AND OBESITY RESEARCH: PROJECT 5

$188,722P20FY2009RRNIH

University Of Louisville, Louisville KY

Investigators

Linked publications & trials

Paper 30338308 Paper 28210871 Paper 27151219 Paper 26799652 Paper 26358111 Paper 26342068 Paper 25917428 Paper 25544597 Paper 25183011 Paper 25048092 Paper 24762972 Paper 24457333 Paper 24367585 Paper 24311618 Paper 24287310 Paper 24024137 Paper 23938401 Paper 23928303 Paper 23785121 Paper 23618531 Paper 23559625 Paper 23421427 Paper 23408289 Paper 23395176 Paper 23385064 Paper 23381845 Paper 23353822 Paper 23335157 Paper 23313711 Paper 23308291 Paper 23298867 Paper 23262638 Paper 23253450 Paper 23144891 Paper 23099819 Paper 23092951 Paper 23092819 Paper 23069475 Paper 23043160 Paper 22954622 Paper 22926941 Paper 22896587 Paper 22887866 Paper 22879597 Paper 22844439 Paper 22686559 Paper 22627060 Paper 22609213 Paper 22426702 Paper 22418586 Paper 22408028 Paper 22404117 Paper 22374140 Paper 22228760 Paper 22140461 Paper 21957201 Paper 21915069 Paper 21908791 Paper 21873502 Paper 21872656 Paper 21846869 Paper 21784079 Paper 21742977 Paper 21691899 Paper 21673308 Paper 21659729 Paper 21627859 Paper 21527748 Paper 21502305 Paper 21478260 Paper 21371710 Paper 21296056 Paper 21276782 Paper 21275902 Paper 21223971 Paper 21147079 Paper 21126940 Paper 21113131 Paper 21071715 Paper 20935678 Paper 20876116 Paper 20709806 Paper 20678513 Paper 20651294 Paper 20640946 Paper 20609918 Paper 20595651 Paper 20538586 Paper 20513478 Paper 20036878 Paper 20034506 Paper 19926880 Paper 19881912 Paper 19752329 Paper 19734355 Paper 19729598 Paper 19682479 Paper 19651811 Paper 19061876

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Elucidation of the roles of miR-301a in hyperglycemic injury and secondary diabetic complications is the main focus of this project. We have proposed three aims: Aim #1 will examine the role of miR-301a in proliferation and migration of SMC cultured in the presence of normal or high glucose and determine whether miR-301a is over expressed in injured carotid artery of diabetic and non-diabetic mice. Aim #2 will delineate the molecular mechanism by which hyperglycemia and NF-kappaB regulates the expression of miR-301a. Aim #3 will determine whether repressing miR-301a expression prevents hyperproliferation of SMC in situ.

View original record on NIH RePORTER →